MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 558240 | Name: KU-2285

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KU-2285 is a potent hypoxic cell radiosensitizer. At less than 100 mg/kg, KU-2285 sensitized SCCVII tumors more than MISO and SR-2508 by fractionated irradiation. KU-2285 entered clinical trials in late 1990s.

Chemical Structure

KU-2285
KU-2285
CAS#121077-11-0

Theoretical Analysis

MedKoo Cat#: 558240

Name: KU-2285

CAS#: 121077-11-0

Chemical Formula: C8H10F2N4O4

Exact Mass: 264.0670

Molecular Weight: 264.19

Elemental Analysis: C, 36.37; H, 3.82; F, 14.38; N, 21.21; O, 24.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
KU2285; KU-2285; KU 2285.
IUPAC/Chemical Name
2,2-difluoro-N-(2-hydroxyethyl)-3-(2-nitro-1H-imidazol-1-yl)propanamide
InChi Key
VOXUFOPZGRTSJY-UHFFFAOYSA-N
InChi Code
InChI=1S/C8H10F2N4O4/c9-8(10,6(16)11-2-4-15)5-13-3-1-12-7(13)14(17)18/h1,3,15H,2,4-5H2,(H,11,16)
SMILES Code
O=C(NCCO)C(F)(F)CN1C=CN=C1[N+]([O-])=O
Appearance
Solid powder
Purity
>98%
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        

Preparing Stock Solutions

The following data is based on the product molecular weight 264.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shibamoto Y, Ohshio G, Hosotani R, Nishimura Y, Manabe T, Imamura M, Abe M. A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy. Br J Cancer. 1997;76(11):1474-9. PubMed PMID: 9400944; PubMed Central PMCID: PMC2228186. 2: Shibamoto Y, Takahashi M, Abe M. A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy. Radiother Oncol. 1996 Jul;40(1):55-8. PubMed PMID: 8844888. 3: Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation. Jpn J Cancer Res. 1996 Jan;87(1):98-104. PubMed PMID: 8609056. 4: Oya N, Shibamoto Y, Shibata T, Murata R, Iwai H, Sugiyama T, Abe M. KIN-804 vs. KU-2285 as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):595-600. PubMed PMID: 8005822. 5: Iwai H, Matsuno E, Sasai K, Shibamoto Y, Abe M. Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):591-4. PubMed PMID: 8005821. 6: Shibata T, Shibamoto Y, Oya N, Sasai K, Murata R, Ishigaki T, Abe M. Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):587-90. PubMed PMID: 8005820. 7: Shibamoto Y, Kitakabu Y, Murata R, Oya N, Shibata T, Sasai K, Takahashi M, Abe M. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):583-6. PubMed PMID: 8005819. 8: Oya N, Shibamoto Y, Sasai K, Sugiyama T, Abe M. In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1113-9. PubMed PMID: 8262836. 9: Shibamoto Y, Streffer C, Sasai K, Oya N, Abe M. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int J Radiat Biol. 1992 Apr;61(4):473-8. PubMed PMID: 1349329. 10: Sasai K, Fushiki M, Yukawa Y, Suyama S, Iwai H, Shibamoto Y, Nishimoto S, Takahashi M, Abe M. In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation. Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1231-4. PubMed PMID: 1938521. 11: Sasai K, Nishimoto S, Shimokawa K, Hisanaga Y, Kitakabu Y, Shibamoto Y, Zhou L, Wang J, Takahashi M, Kagiya T, et al. A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1249-54. PubMed PMID: 1828462.

View History

JUN 01803

JUN 01803

Featured